Furacilin Avexima - instructions for use, dose, side effects, contraindications

Excipients: tartaric acid 375 mg, sodium hydrogen carbonate 299 mg, sodium carbonate 325 mg, sodium chloride 100 mg, macrogol 20,000 to 65 mg, povidone medium molecular weight 16 mg.

Description:

Round, flat-cylindrical tablet form, from light yellow to yellow with interspersed, chamfered on both sides. Roughness of the surface of the tablet is allowed.

Pharmacotherapeutic group:Antimicrobial agent-nitrofuran

ATX: & nbsp

D.08.A.F.01 Nitrofural

Pharmacodynamics:

Antimicrobial agent, a derivative of nitrofuran. Bacterial flavoproteins restoring the 5-nitro group form highly reactive amino derivatives, which can cause conformational changes in proteins (including ribosomal) and other macromolecules, leading to the death of bacteria. It is active against Gram-positive and Gram-negative bacteria, incl. Staphylococcus spp., Streptococcus spp., Escherichia coli, Clostridiumperfringens.Sustainability develops slowly and does not reach a high degree.

Pharmacokinetics:

With local and external application, the absorption is insignificant.

Indications:

As part of complex therapy: topically: acute tonsillitis (tonsillitis), stomatitis, gingivitis, blepharitis, conjunctivitis; externally: purulent wounds, pressure sores, burns II-III degree, minor damage to the skin (including abrasions, scratches, cracks, cuts).

Contraindications:

Hypersensitivity to nitrofural, nitrofuran derivatives and / or other components of the drug, bleeding, allergic dermatosis, marked renal dysfunction.

Pregnancy and lactation:

Application in pregnancy and during breastfeeding is possible if the intended benefit to the mother exceeds the potential risk to the fetus or child.

Dosing and Administration:

Locally, externally in the form of 0.02 % freshly prepared aqueous solution: immediately before use, one tablet (20 mg furatsilina), dissolved in 100 ml of distilled water at room temperature or in warm boiled water.

With acute tonsillitis (angina), stomatitis, gingivitis - mouth and throat rinsing with a warm 0.02 % solution of 100 ml 2-3 times a day. With blepharitis, conjunctivitis is instillation of 0.02% solution into the conjunctival sac. Outer 0,02% aqueous solution water the wounds and apply moist bandages.

Duration of treatment - according to the indications depending on the nature and localization of the affected area.

If symptoms persist, it is recommended that you consult a doctor.

Side effects:

Allergic reactions are possible: itching, dermatitis.

If any of the side effects listed in the manual are aggravated, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose:

No cases of overdose have been reported.

Interaction:

Not studied.

Effect on the ability to drive transp. cf. and fur:

The drug does not affect the ability to drive vehicles or engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Form release / dosage:

The effervescent tablets are 20 mg.

Packaging:

2 tablets per contour non-cellular package (strip) of packaging material combined on a paper basis.

For 10, 15, 20, 25 or 30 tablets in a plastic tube, sealed with a plastic lid with a desiccant and first opening control.

For 10, 15, 20, 25 or 30 tablets in a jar of polymer materials made of low density polyethylene, sealed with a plastic lid with a desiccant and first opening control.

5 contour non-jawed packages (strips) with instructions for medical use are placed in a pack of cardboard.

1 plastic tube or jar of polymer materials with instructions for medical use are placed in a pack of cardboard.

Storage conditions:

Store in a dry, dark place at a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

2 years.

After expiration date the drug should not be used.

Terms of leave from pharmacies:Without recipe

Registration number:LP-002980

Date of registration:29.04.2015 / 25.12.2017

Expiration Date:29.04.2020

The owner of the registration certificate:AVEKSIMA, JSC AVEKSIMA, JSC Russia

Manufacturer: & nbsp

IRBITSK HFZ, OJSC Russia

Information update date: & nbsp20.03.2018

Illustrated instructions

Instructions

Furacilin Avexime (Furacilin Avexima)